EGRX STOCKHOLDERS: Robbins LLP Reminds Eagle Pharmaceuticals Shareholders of Pending Lead Plaintiff Deadline – February 9, 2024
26. Januar 2024 12:33 ET
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
30. Dezember 2023 11:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
Eagle Pharmaceuticals Shareholders Still Have Time to Participate in the EGRX Class Action; Contact Robbins LLP Today
29. Dezember 2023 08:00 ET
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
EGRX Alert: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Highlights Upcoming Deadline
21. Dezember 2023 13:53 ET
|
Kaplan Fox & Kilsheimer LLP
NEW YORK, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP reminds investors that a complaint has been filed on behalf of investors that purchased or otherwise acquired Eagle...
EGRX Class Action Alert: Robbins LLP Reminds Investors of Lead Plaintiff Deadline in Eagle Pharmaceuticals, Inc. Class Action
18. Dezember 2023 15:12 ET
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
Kaplan Fox & Kilsheimer LLP Reminds Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
17. Dezember 2023 08:01 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox alerts investors of class action and upcoming deadline.
Eagle Pharmaceuticals Investor Update: Kaplan Fox & Kilsheimer LLP Notifies Eagle Pharmaceuticals Investors of a Class Action and Upcoming Deadline
13. Dezember 2023 12:30 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox notifies investors of Class Action filed against Eagle Pharmaceuticals.
Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Eagle Pharmaceuticals, Inc. (EGRX)
12. Dezember 2023 00:42 ET
|
Robbins LLP
Eagle Pharmaceuticals, Inc. (EGRX) Misled Investors and Overstated its Revenue
EGRX Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX)
07. Dezember 2023 08:00 ET
|
Kaplan Fox & Kilsheimer LLP
Kaplan Fox & Kilsheimer LLP is investigating potential claims on behalf of investors who purchased securities of Eagle Pharmaceuticals, Inc.
Eagle Pharmaceuticals, Inc. (NASDAQ: EGRX) Investors: Please contact the Portnoy Law Firm to recover your losses
05. Dezember 2023 15:59 ET
|
Portnoy Law
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, Dec. 05, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Eagle Pharmaceuticals, Inc....